Hypoxia-inducible factor-targeting prodrug TOP3 combined with gemcitabine or TS-1 improves pancreatic cancer survival in an orthotopic model.
Pancreatic cancer is one of the most lethal digestive system cancers with a 5-year survival rate of 4-7%. Despite extensive efforts, recent chemotherapeutic regimens have provided only limited benefits to pancreatic cancer patients. Gemcitabine and TS-1, the current standard-of-care chemotherapeutic drugs for treatment of this severe cancer, have a low response rate. Hypoxia is one of the factors contributing to treatment resistance. Specifically, overexpression of hypoxia-inducible factor, a master transcriptional regulator of cell adaption to hypoxia, is strongly correlated with poor prognosis in many human cancers. TAT-ODD-procaspase-3 (TOP3) is a protein prodrug that is specifically processed and activated in hypoxia-inducible factor-active cells in cancers, leading to cell death. Here, we report combination therapies in which TOP3 was combined with gemcitabine or TS-1. As monotherapy, gemcitabine and TS-1 showed a limited effect on hypoxic and starved pancreatic cancer cells, whereas co-treatment with TOP3 successfully overcame this limitation in vitro. Furthermore, combination therapies of TOP3 with these drugs resulted in a significant improvement in survival of orthotopic pancreatic cancer models involving the human pancreatic cancer cell line SUIT-2. Overall, our study indicates that the combination of TOP3 with current chemotherapeutic drugs can significantly improve treatment outcome, offering a promising new therapeutic option for patients with pancreatic cancer.
School of Life Science and Technology, Tokyo Institute of Technology, Yokohama, Japan.
Ngoc Thi Hong
NT
Hoang
School of Life Science and Technology, Tokyo Institute of Technology, Yokohama, Japan.
Tetsuya
T
Kadonosono
School of Life Science and Technology, Tokyo Institute of Technology, Yokohama, Japan.
Takahiro
T
Kuchimaru
School of Life Science and Technology, Tokyo Institute of Technology, Yokohama, Japan.
Shinae
S
Kizaka-Kondoh
D000818:Animals; D045744:Cell Line, Tumor; D003841:Deoxycytidine / Q000008:administration & dosage / Q000031:analogs & derivatives* / Q000494:pharmacology; D005472:Fluorouracil / Q000494:pharmacology; D006801:Humans; D051793:Hypoxia-Inducible Factor 1 / Q000037:antagonists & inhibitors*; D008297:Male; D051379:Mice; D008807:Mice, Inbred BALB C; D010190:Pancreatic Neoplasms / Q000378:metabolism* / Q000473:pathology*; D011355:Prodrugs / Q000378:metabolism* / Q000494:pharmacology; D011993:Recombinant Fusion Proteins / Q000378:metabolism* / Q000494:pharmacology; D017640:Silicates / Q000008:administration & dosage / Q000494:pharmacology*; D016019:Survival Analysis; D014025:Titanium / Q000008:administration & dosage / Q000494:pharmacology*; D000072258:Tumor Hypoxia; D023041:Xenograft Model Antitumor Assays; D000093542:Gemcitabine
D051793:Hypoxia-Inducible Factor 1; D011355:Prodrugs; D011993:Recombinant Fusion Proteins; D017640:Silicates; C498363:TOP3 fusion protein; D003841:Deoxycytidine; C103828:titanium silicide; D014025:Titanium; D005472:Fluorouracil; D000093542:Gemcitabine
Gemcitabine; TOP3; TS-1; hypoxia inducible factor; pancreatic cancer